Google Scholar: cites
Influence of cannabis use on incidence of psychosis in people at clinical high risk
Chester, Lucy A. (King's College London)
Valmaggia, Lucia (King's College London)
Kempton, Matthew J (King's College London)
Chesney, Edward (King's College London)
Oliver, Dominic (Warneford Hospital)
Hedges, Emily P. (King's College London)
Klatsa, Elise (King's College London)
Stahl, Daniel (King's College London)
van der Gaag, Mark (Parnassia Psychiatric Institute)
de Haan, Lieuwe (Arkin Amsterdam)
Nelson, Barnaby (Orygen)
McGorry, Patrick (Orygen)
Amminger, G. Paul (Orygen)
Riecher-Rössler, Anita (University of Basel)
Studerus, Erich (University of Basel)
Bressan, Rodrigo Affonseca (Universidade Federal de São Paulo)
Barrantes-Vidal, Neus (Universitat Autònoma de Barcelona. Departament de Psicologia Clínica i de la Salut)
Krebs, Marie-Odile (University Paris Descartes)
Glenthøj, Birte (University of Copenhagen)
Nordentoft, Merete (University of Copenhagen)
Ruhrmann, Stephan (University of Cologne)
Sachs, Gabriele (Medical University of Vienna)
McGuire, Philip (Warneford Hospital)

Data: 2023
Resum: Evidence for case-control studies suggests that cannabis use is a risk factor for the development of psychosis. However, there have been limited prospective studies and the direction of this association remains controversial. The primary aim of the present study was to examine the association between cannabis use and the incidence of psychotic disorders in people at clinical high risk of psychosis. Secondary aims were to assess associations between cannabis use and the persistence of psychotic symptoms, and with functional outcome. Current and previous cannabis use were assessed in individuals at clinical high risk of psychosis (n = 334) and healthy controls (n = 67), using a modified version of the Cannabis Experience Questionnaire. Participants were assessed at baseline and followed up for 2 years. Transition to psychosis and persistence of psychotic symptoms were assessed using the Comprehensive Assessment of At-Risk Mental States criteria. Level of functioning at follow up was assessed using the Global Assessment of Functioning disability scale. During follow up, 16. 2% of the clinical high-risk sample developed psychosis. Of those who did not become psychotic, 51. 4% had persistent symptoms and 48. 6% were in remission. There was no significant association between any measure of cannabis use at baseline and either transition to psychosis, the persistence of symptoms, or functional outcome. These findings contrast with epidemiological data that suggest that cannabis use increases the risk of psychotic disorder.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Matèria: THC ; Clinical high-risk ; Longitudinal ; Psychotic disorders ; Substance use
Publicat a: Psychiatry and Clinical Neurosciences, Vol. 77 Núm. 9 (september 2023) , p. 469-477, ISSN 1440-1819

DOI: 10.1111/pcn.13555
PMID: 37070555


19 p, 599.0 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2024-05-17, darrera modificació el 2025-03-25



   Favorit i Compartir